update on Apr 13 Abbott has continued to expand accessibility to our COVID-19 tests by ramping up production and shipping to more customers, helping healthcare providers on the frontlines. Here’s an update: ID NOW – Our rapid, portable testing instrument used in urgent care clinics, hospital emergency departments, and physicians' offices Through Saturday, April 11, we have shipped 566,000 of our rapid ID NOW tests to all 50 states, Washington DC, Puerto Rico and the Pacific Islands. The majority of these tests have been sent to outbreak hotspots and we've asked that customers prioritize front-line health care workers and first responders. We're currently manufacturing 50,000 tests per day, plan to increase ID NOW manufacturing capacity to 2 million tests a month by June and are working to expand beyond that. m2000 – Our large, high-volume laboratory instrument We have shipped more than 1 million tests to customers across the U.S. We're also shipping these tests to customers throughout the world. There are approximately 200 m2000 instruments in hospital, academic center and reference labs throughout the U.S. APR 3 2020 We began distributing our rapid point-of-care COVID-19 tests for our ID NOW system on Tuesday, March 31. By the end of today we will have shipped more than 190,000 rapid tests to customers in 21 states. We're producing 50,000 tests every day now and we'll continue to ship daily to more customers in more places. We're also continuing to ramp up our ID NOW manufacturing and plan to increase capacity to 2 million tests a month by June and are working to expand beyond that. We've been in close coordination with U.S. federal and state authorities – as well as our customers in urgent care clinics, hospital emergency departments, and physicians' offices – to ensure ID NOW instruments and tests are sent to outbreak hotspots. While customers ultimately determine how our tests are deployed, we would like to prioritize front-line healthcare workers and first responders because we believe this is the best way to support the nation’s healthcare infrastructure. Beyond delivering our tests, we are also doing all we can to monitor the deployment of the rapid tests and to avoid hoarding or price-gouging in secondary markets. A rapid test is one part of the solution, not the only one. Our m2000 RealTime molecular laboratory instrument, for example, can run 470 tests a day and give results in about 6.5 hours. Importantly, we're now able to produce 1 million tests a week for our m2000 laboratory system. To date, we've shipped nearly 1 million tests to customers across the U.S. and have begun to ship tests to other countries around the world. At Abbott, we have a saying, "we make our products as if they are for our own families." We and our families live in the same communities around the country and around the world that you do. We understand our responsibility. We know the stakes. We know 50,000 rapid tests a day are not enough. We can see the gaps also. But we're not stopping here. We’re working 24/7 to make as many tests as we can and create the next round of needed tests. Our scientists continue to work on additional COVID-19 tests across the spectrum of our diagnostic instruments, including lateral flow and antibody tests. Our goal is to provide more testing, and to get our tests to more places around the world. We're proud to be able to contribute in this fight and are committed for the duration.
汗，怎么有这一出？居然不能一个人同时管几台？
我没记错的话每个病人要扎手指头取血。一个病人弄下来要10来分钟
纽约不是有几万志愿者吗？现在看起来医院本身的员工够了，怎么不让这些医务人员去帮忙呢？还是说用这个机器要有专门培训的人？
都已经住院了为什么还要用？是检查是否康复吗？纽约总共住院的人也不太多。
我们这不是纽约，住院的重症需要快速排查是不是新冠，从而可以节省PPE 。Drive test一般是轻症，反正都是回家去，不需要快速出结果
谢谢解惑！mm要是在医院工作希望多保重！